Metastatic Breast Cancer Clinical Trials in Duarte, California

5 studies are recruiting for metastatic breast cancer in Duarte, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

   This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven cohorts will be enrolled in parallel in this study: Cohort 1…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope - Duarte, Duarte, California

   Locations

   53 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT03424005 on ClinicalTrials.gov

2. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

   First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   44 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06625775 on ClinicalTrials.gov

3. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

   This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   231 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT06982521 on ClinicalTrials.gov

4. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

   This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   192 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT05894239 on ClinicalTrials.gov

5. Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

   Phase I/II study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1*).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   Minerva Biotechnologies Corporation

   See if you can join NCT04020575 on ClinicalTrials.gov